Role of Fosfomycin, Linezolid, and Rifampin in Treating Prostate Infections

Fosfomycin in Prostate Infections

The European Association of Urology (EAU) recommends Fosfomycin trometamol as an alternative antibiotic for transrectal prostate biopsy prophylaxis, with a dosing regimen of 3g before and 3g 24-48h after biopsy 1, 2

Linezolid is classified as a "Group C: other second-line agent" for genitourinary tuberculosis (GUTB) when multidrug resistance is present, according to the European Association of Urology (EAU) guidelines 1, 2, 3
Linezolid has activity against gram-positive organisms and can inhibit production of staphylococcal toxins, as reported by the Clinical Infectious Diseases journal 4
Linezolid may be considered in combination therapy for vancomycin-resistant enterococci (VRE) infections, which can occasionally cause prostatitis, according to the Journal of Microbiology, Immunology and Infection 5

Rifampin is primarily recommended as part of the standard treatment regimen for genitourinary tuberculosis at a dose of 10 mg/kg every 24 hours (maximum daily dose 600 mg), according to the European Association of Urology (EAU) guidelines 1, 6

The European Association of Urology (EAU) guidelines advise that combination therapy with multiple antibiotic classes for prophylaxis contravenes antibiotic stewardship principles 1
The use of these agents should follow antimicrobial stewardship principles, particularly for linezolid and rifampin which have important roles in treating other serious infections, as recommended by the European Association of Urology (EAU) guidelines 1